In a bid to reduce its reliance on Jakafi® (ruxolitinib), Incyte has agreed to partner with MorphoSys to develop and commercialise its anti-CD19 antibody, tafasitamab, globally. Tafasitamab is a Fc-engineered antibody currently in development for the treatment of diffuse large B cell lymphoma and chronic lymphocytic leukaemia. Interestingly, the deal comes less than two weeks after Incyte’s JAK1 inhibitor, itacitinib, for the treatment of graft-versus-host disease failed a Phase III trial, leaving Incyte short on late-stage therapies.